Skip to main content
Premium Trial:

Request an Annual Quote

EraGen Partners with Illumina to Develop Molecular Dx Assays

NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.

Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.

Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.

Financial terms of the agreement were not disclosed.

"Our newly formed relationship with Illumina further validates our MultiCode technology's versatile application in the development and commercialization of molecular-based assays for the clinical market," Irene Hrusovsky, president and CEO of EraGen, said in a statement.

EraGen's MultiCode technology detects RNA and DNA targets by combining multiplexed PCR with its ISO bases, which are structurally similar to standard nucleobases but have altered base-pairing specificity.

EraGen said that the pact is part of its strategy to continue expanding its commercial efforts in the molecular diagnostics market.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.